[Skip to Navigation]
Sign In
Clinical Trials Update
November 22/29, 2022

Intranasal COVID-19 Vaccine Disappointing in First-in-Human Trial

JAMA. 2022;328(20):2003. doi:10.1001/jama.2022.18485

The first-in-human study of intranasal COVID-19 vaccination with an adenovirus-vector vaccine did not induce a consistent mucosal antibody response or a strong systemic response.

The first part of the phase 1 trial included 30 healthy adults who had never received a SARS-CoV-2 vaccine. The intranasal (IN) vaccination tested in the trial used the existing formulation of the ChAdOx1 nCoV-19 intramuscular (IM) vaccine developed by University of Oxford/AstraZeneca. Participants received either a low dose, mid dose, or high dose of the IN vaccine. The volunteers were then randomly assigned to receive 1 dose or 2 doses. The 2-dose group received their second IN vaccination 28 days later.

Add or change institution